Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Articles online first > Minerva Cardioangiologica 2017 Nov 20

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA CARDIOANGIOLOGICA

Rivista sulle Malattie del Cuore e dei Vasi


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

Minerva Cardioangiologica 2017 Nov 20

DOI: 10.23736/S0026-4725.17.04569-8

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Sutureless aortic valve and TAVI: pros and cons

Thierry FOLLIGUET

Chirurgie Cardiaque Vasculaire & Transplantation, Institut Lorrain du Coeur & des Vaisseaux Louis Mathieu, Centre Hospitalier Universitaire Brabois, Université de Lorraine, Vandoeuvre Les Nancy, France


PDF  


Aortic valve replacement with biological heart valves remains the gold standard for treating operable older patients with symptomatic aortic stenosis. In the last years trans aortic valve implantation (TAVI) has been shown to be superior to medical treatment in high risks patients with severe aortic stenosis. The transfemoral TAVI route has been also found in randomized controlled trials to be as good if not superior to standard AVR at 5 years in high risk patients. In intermediate risks patients TAVI was found in randomized controlled trials as a noninferior alternative to surgery, with a different pattern of adverse events associated with each procedure. In retrospective propensity matched analysis the use of TAVI in patients with an intermediate to high risk profile was associated with a significantly higher incidence of perioperative complications and decreased survival at short and mid-term when compared with conventional surgery and sutureless valve implantation. More data is needed to draw a firm conclusion comparing the two treatments in intermediate risk patients. Sutureless bioprosthesis may represent a viable alternative to standard bioprosthesis for intermediate and high risks patients when having conventional surgery.


KEY WORDS: Aortic valve - Sutureless valve

inizio pagina

Publication History

Article first published online: November 20, 2017
Manuscript accepted: November 14, 2017
Manuscript received: November 10, 2017

Per citare questo articolo

Folliguet T. Sutureless aortic valve and TAVI: pros and cons. Minerva Cardioangiol 2017 Nov 20. DOI: 10.23736/S0026-4725.17.04569-8

Corresponding author e-mail

t.folliguet@chru-nancy.fr